Susan Dent, MD, delves into the exploration of front-line treatment options for triple-positive breast cancer and examines strategies for restaging in the event of disease progression after first-line therapy.
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer
Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30